Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. - Wikidata - wikimedia - TriplyDB

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

http://www.wikidata.org/entity/Q34526421

about

Erythropoietin or darbepoetin for patients with cancer Drug therapy for the management of cancer-related fatigue Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data Drug therapy for the management of cancer related fatigue Erythropoietin for patients with malignant disease Erythropoietin or Darbepoetin for patients with cancer The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival.Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.Current and future use of hematopoietic growth factors in cancer medicine.Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.Erythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis.Erythropoiesis-stimulating agent use after changes in medicare reimbursement policies.Erythropoietin action in stress response, tissue maintenance and metabolism.Transfusions and patient burden in chemotherapy-induced anaemia in France Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.Cancer-related fatigue: evolving concepts in evaluation and treatment.Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials.Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia.Risks of Venous Thromboembolism and Mortality Associated With Erythropoiesis-Stimulating Agents for the Treatment of Cancer-Associated Anemia.Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia.Epoetin beta for the treatment of chemotherapy-induced anemia: an update.Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer.Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues.Evaluation and management of fatigue in oncology: a multidimensional approach.Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusions Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.Pathophysiology of cancer-related fatigue Management of anemia in patients with cancer.Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.Can erythropoietin therapy improve survival?Evolving treatment strategies for anaemia in cancer: experience with epoetin beta.Population pharmacokinetics of darbepoetin alfa in healthy subjects Canadian supportive care recommendations for the management of anemia in patients with cancer.

P2860

Q24202335-B366C11A-B9AC-4E9E-9F55-9BF9B56DFD6A Q24234267-6C9509F0-B0F6-4EB8-85FA-EF85814B0092 Q24240202-712116F2-52D5-47A9-91F6-7A44B8AD79E3 Q24242050-D01C9CB7-18BF-4D37-97A8-79B805C9CF8D Q24245427-288A91B8-220A-455D-BF45-52B38251A00B Q24245464-804F21DF-D81E-463D-A01C-F0044B872863 Q30453014-681405ED-F828-4A45-9333-B967645DA1E9 Q30803363-20723B08-9ACF-44D8-9932-145B4E1339DF Q33243661-5D23BC9F-2533-4209-9A2F-8D35F25EAA0B Q33243739-F53E776A-CD8C-48FE-964C-6BE46B14BD39 Q33367026-AAFB4EF2-95B9-4AE6-B398-4DEFB183F986 Q33499897-12E71E68-4EED-49EE-BBF2-76C3445B364E Q33630871-BA27D657-2580-4A77-BA3A-3981A70FEE65 Q33727356-4EE7B9FB-6116-4BA5-9B28-EFB29D26E2F2 Q33827405-B5192F17-C870-43C5-B0A7-43FD36EA3054 Q33890476-C5D7C818-36D0-4366-A86B-7C730D23C37A Q33907747-E9815914-38FC-4388-8C90-6C32C605F0C8 Q33937375-DD0012B5-5FC7-4853-BBF8-CCAC1DDFF8AF Q34100489-6CA9733D-2D20-4A58-BA5C-2162CD47031F Q34535702-3D91743B-BF6F-466F-9F07-27567062AAA1 Q34542897-548F3A92-E012-454A-A93E-0B0B4AF2BC0C Q34554073-7E38A6E6-B31F-45DF-AF35-BEBDC950622D Q34635638-A2FCEBC8-D3B0-4A01-B95C-A1D6CB0D3E07 Q35144050-491E6047-9E2F-438D-AB9E-CD5C9C876002 Q35164312-DFB92299-224B-4120-85B1-5205929CC1AD Q35166812-878280EB-FCF0-4BFD-8499-120A4437A03F Q35168681-2CE6FC7D-3C38-43BE-B261-CA871997986E Q35187820-F75CC4B8-439C-4CEB-92CA-B6381D78BEC9 Q35217404-3B187B8B-1F3F-401B-9F07-426922D4289E Q35245106-A8845632-84D9-4FA9-8373-427F168D8894 Q35432469-2A37FE5C-6C10-4207-8447-2B5529E3FDEF Q35583842-00F60236-1969-45F2-A232-688922885E10 Q35696941-142A11E9-554E-416D-AD3F-61A9FF7BB6BE Q35763344-C75C3488-755B-4588-9BEE-3D317E9D77F3 Q35783062-ECC66315-D310-4592-9DAF-C18914DED477 Q35858979-8F9FC00A-103A-4456-814F-72561C389294 Q35919220-D26AC671-AB6C-4285-AF89-2B81F8D9735C Q35919230-29E6809E-1678-44EE-8204-7A9D6CEFF8CB Q36024876-8FB1667F-A4CD-43D5-8722-FD2F8D729FC0 Q36029750-724FF447-AD06-4D8F-A9CD-0B5B624118BB

P2860

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

http://www.wikidata.org/entity/Q34526421

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Double-blind, placebo-controll ...... tients receiving chemotherapy.

@ast

Double-blind, placebo-controll ...... tients receiving chemotherapy.

@en

Double-blind, placebo-controll ...... tients receiving chemotherapy.

@nl

type

label

Double-blind, placebo-controll ...... tients receiving chemotherapy.

@ast

Double-blind, placebo-controll ...... tients receiving chemotherapy.

@en

Double-blind, placebo-controll ...... tients receiving chemotherapy.

@nl

prefLabel

Double-blind, placebo-controll ...... tients receiving chemotherapy.

@ast

Double-blind, placebo-controll ...... tients receiving chemotherapy.

@en

Double-blind, placebo-controll ...... tients receiving chemotherapy.

@nl

P1433

Q34526421-96879ED9-2CDB-4CDA-BECA-35C73E24F81A

P1476

Q34526421-85BC8741-D3E6-4A1A-91A7-CD00A419C795

P2093

Q34526421-0BD1B41A-D4E0-4501-A19C-50E105279BF8

Q34526421-0D4BD513-AA02-46A2-9109-735865A39A43

Q34526421-14615186-359A-4BF9-8A87-796826DB5EEF

Q34526421-165066B4-7C92-47E4-93EF-8686A024BAB6

Q34526421-1DCCAAF5-42A8-4E5C-8EF2-0BE4F35D5022

Q34526421-5EE8C15D-7679-4962-8A14-55D2D4AE7DED

Q34526421-868F1E74-E735-4803-A9B3-8B74AE51C48C

Q34526421-928B3697-C438-44B0-AA6F-1ACA5533D2E5

Q34526421-96ED98E1-EDB6-4F37-8F9F-B47AC631C6AD

Q34526421-A51F1AD7-04BE-4F10-8359-A0D689C606D6

P304

Q34526421-A62BA721-E35C-4938-99C4-23A573D2AE3F

P31

Q34526421-26E951FA-6803-4D36-87B0-AE557AE86641

P356

Q34526421-C7992951-8A2E-4A03-948E-74C2C2BBB321

P407

Q34526421-14B2A7B6-5337-4C6B-BB85-BD698B0AD8A4

P433

Q34526421-7BB132BA-B77C-4212-B44F-A58DF803301C

P478

Q34526421-B6B49B55-5853-44C4-8372-EFF3BE85603F

P577

Q34526421-803014D0-D7B4-465B-AA13-0AE62437F1F4

P5875

Q34526421-1D817D4A-838D-437A-A694-0CA493A4ADEE

P698

Q34526421-98E6AD18-90F8-45B3-BA91-F92ECFEFB771

P921

Q34526421-71F83CCE-0CE7-412F-BD0F-A0FC54F222F7

Q34526421-DE44BA71-1684-4D91-82F4-3E9954F255E8

Q34526421-ED74C4C9-3178-4EDE-8900-EE09CC56671A

Q34526421-F927FE11-9B0B-4EF0-9096-CC8C10F727B7

P356

P1433

Journal of the National Cancer Institute

P1476

Double-blind, placebo-controll ...... tients receiving chemotherapy.

@en

P2093

Alan B Colowick

http://www.w3.org/2001/XMLSchema#string

Albert Font

http://www.w3.org/2001/XMLSchema#string

Aranesp 980297 Study Group

http://www.w3.org/2001/XMLSchema#string

Bartomeu Massuti

http://www.w3.org/2001/XMLSchema#string

Dianne Tomita

http://www.w3.org/2001/XMLSchema#string

Fernando Barata

http://www.w3.org/2001/XMLSchema#string

Jaromir Musil

http://www.w3.org/2001/XMLSchema#string

Jenni Gateley

http://www.w3.org/2001/XMLSchema#string

Johan Vansteenkiste

http://www.w3.org/2001/XMLSchema#string

Michael Fiegl

http://www.w3.org/2001/XMLSchema#string

P304

1211-1220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/94.16.1211

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273041523

http://www.w3.org/2001/XMLSchema#string

P698

12189224

http://www.w3.org/2001/XMLSchema#string

P921

Darbepoetin alfa

phase III clinical trial